Cargando…
28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
Metastatic renal cell carcinoma (mRCC) has been one of the most treatment-resistant cancers because of its unpredictable clinical course, resistance to chemo- and radiotherapy, and the limited response to immunotherapy and targeted agents. We present a case of long-term survival, that is, 28 years,...
Autores principales: | Magdy, A., Bretterbauer, K., Hruby, S., Kunit, T., Colleselli, D., Janetschek, G., Mitterberger, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355604/ https://www.ncbi.nlm.nih.gov/pubmed/25810943 http://dx.doi.org/10.1155/2015/523258 |
Ejemplares similares
-
Laparoscopic Treatment of a Spontaneously Ruptured Kidney (Wunderlich Syndrome)
por: Bretterbauer, Katharina Maria, et al.
Publicado: (2015) -
Non-ischemic laparoscopic partial nephrectomy using 1318-nm diode laser for small exophytic renal tumors
por: Drerup, Martin, et al.
Publicado: (2018) -
Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015) -
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014) -
SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)